NCT03881605: MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients With Triple Negative or HER2+ MBC

NCT03881605
Breast Cancer Type: HER2+, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Not Applicable
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have metastatic diagnosis within 12 weeks prior to study enrollment
Exclusions: Patients with brain metastases
https://ClinicalTrials.gov/show/NCT03881605

Comments are closed.

Up ↑